A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, May 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

news: 2 news outlets

twitter: 4 X users

Citations

dimensions_citation: 44 Dimensions

Readers on

mendeley: 82 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

Anti-inflammatory drugs may hold potential in Alzheimer's treatment

Medical News Today, 27 Jul 2023

Share on PinterestPictured, University of Kentucky’s Sanders-Brown Center on Aging Director Dr.

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.

Alzforum, 04 Jun 2021

Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens P, REVERSE-SD Study Investigators.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.